Official Launch of ATTOPOLIS B2B Platform

Official Launch of ATTOPOLIS B2B Platform congratulated by Ambassador of The Singapore Embassy in Germany & the Singapore leading Agencies



Singapore, Singapore Dec 7, 2022 (Issuewire.com) - Singapore Ambassador, Mr. Lawrence Bay, congratulates ARQon (Asia Regulatory & Quality Consultancy) on the official launch of the ATTOPOLIS platform. ATTOPOLIS is a B2B International Medical Digital Platform, which soft-launched at Singapore's Medical Trade Fair Asia and had the official launch at MEDICA Messe Düsseldorf today at Singapore Pavilion with participation from various international Trade Association and Embassies, Manufacturers, Distributors, and Incubators.

At the launch, the leading public and private sectors from Singapore were invited to open the official launch of ATTOPOLIS with ARQon, including Enterprise Singapore (ESG), Racer and Singapore MedTech Consortium (SMC), and National Healthcare Innovation Centre (NHIC). Together, we aim to help local companies to grow their business and expand internationally.

ATTOPOLIS will lead, connect and globalize MedTech Companies and Professionals in this all-in-one B2B digital ecosystem and the business solution for the MedTech industry.

The platform allows sharing of the latest global and local news and events for the MedTech industry. The AttoTrade and AttoService features provide Manufacturers and Service Providers to list their products and services in the platform free of charge while ATTOPOLIS will focus on value-adding services, advertisement, and the core competency supporting regulatory approval to facilitate companies on market entry.

Singapore has been known for its National Initiatives to promote fast and efficient transactions on all eservices with the Government. ATTOPOLIS is an aspirational vision for the industry from the founder, May Ng, to fulfill an unmet need following an extensive career in the MedTech industry, and as a former medical device regulator in Singapore for the implementation of the medical device control framework and the online MEDICS registration system.

For more information about ATTOPOLIS, visit www.attopolis.com

MEDICA & COMPAMED DUSSELDORF

The largest Medical Expo in the world showcases at least 5500 companies and spans over 18 Halls. Close to 120,000 trade professionals from manufacturers, distributors, researchers, hospitals, and trade organization stakeholders for the latest product trends and collaboration opportunities in healthcare.

ARQon Group

ARQon Group was established in 2014, with its headquarters in Singapore, and has expanded to 10 offices globally. The group specializes in Global Regulatory approval of Medical Devices and Drugs. With its growing network and extensive expertise in the MedTech industry, ARQon opened MedtechBOSS (Business One-Stop Service) for business matching with Trade Embassies, IMDS (International Medical Device School) with Temasek Polytechnic under SkillsFuture SSG on design to commercialization training and developed ATTOPOLIS, the next leading B2B platform for MedTech industry.

ARQon has helped many local startup companies e.g., EyRIS AI, MirXes IVD, EndoMaster robotic, and overseas companies Invisalign US, Device Technologies DTG Australia, and MedAlliance Europe to gain market access overseas and Southeast Asia.

May Ng, the founder currently is also on the regulatory panel for Singapore NHIC, IPI, and South Korea KHIDI. She served as ASEANMed Co-chair, Singapore Manufacturing Federation Council, and MedTech Pro-Enterprise subcommittee chair. Prior to ARQon, she was the Health Sciences Authority regulator implementing the control of the medical device and online systems, leading global approval for drug-coated stents in the Biosensors international group and a few Singapore startups.

Media Contact

ATTOPOLIS@ARQon-Asia Regulatory & Quality Consultancy

connect@arqon.com

69808213

2985 Jalan Bukit Merah, #03-3A SINGAPORE MANUFACTURING FEDERATION BUILDING, Singapore 159457

Source : ARQon Pte Ltd (Asia Regulatory & Quality Consultancy For Medical Device & Drug)

See on IssueWire